MedPage Today reported that “newly initiated use of an SGLT2 inhibitor was associated with a roughly twofold greater risk of diabetic ketoacidosis versus new initiation of a DPP4 inhibitor,” investigators found after examining “data on 50,220 patients with type 2 diabetes from the TruvenMarketScan database of commercially insured patients,” all of whom “were started on an SGLT2 inhibitor or DPP4 inhibitor prior to the FDA warning (April 2013-December 2014).” The findings were published in The New England Journal of Medicine.